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lzheimer’s disease (AD) is one of the most devastat-
ing and costly disorders affecting the aging population.
This disease has an estimated prevalence of up to 40% in
those over age 80.
1 Its financial cost to society has been
estimated at between $70 and $100 billion annually.
2
Currently approved therapies,arguably modest in effect,
focus on symptomatic treatment.
3-5 Preventive strategies,
on the other hand,remain elusive.Better understanding
of this disorder,as well as the development of both pre-
ventive and improved symptomatic treatments,has been
limited by difficulties encountered in clinical diagnosis
and the lack of adequate quantitative biomarkers for the
disease.
Clinical diagnosis depends on the definition of cognitive
deficits and the separation of normal age-related decline
from pathological deterioration.Because the normal range
of variability of cognitive abilities among the aged is
extremely large,it is difficult to quantify precise normative
limits of the normal range.It is commonly understood that
different levels of cognitive functioning are expected from
a 90 year old than a 60 year old,or a university graduate
versus an illiterate person.Instead,the clinical diagnosis of
dementia usually relies on the characterization of intra-
individual decline from premorbid level of functioning.
Typically,however,firm quantitative data about premor-
bid status are lacking, and the diagnostic process relies
instead on interviews at the time of symptomatic onset that
attempt to characterize premorbid performance levels.This
approach is limited in its accuracy,and suffers from possi-
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A
Alzheimer’s disease (AD) is one of the most devastating
and costly disorders affecting the aging population.
Structural imaging (computed tomography [CT] and mag-
netic resonance imaging [MRI]) and functional imaging
(single photon emission computed tomography [SPECT]
and positron emission tomography [PET]) have been eval-
uated for their roles in the imaging diagnosis of AD. We
have reviewed the recent literature to determine the
capabilities of these neuroimaging techniques in com-
parison to current standards of clinical diagnosis. Our
results indicate that there is wide variability in the accu-
racy of clinical assessments, in contrast to a more limited
range of variability of the accuracy of neuroimaging mea-
surements. These results suggest that neuroimaging may
serve an adjunctive role in raising this lower bound of
diagnostic accuracy. Furthermore, we suggest that neuro-
imaging should be considered: (i) when clinical expertise
is insufficient; (ii) as a complement to specific likelihood
ratios; and (iii) in specific types of patients, for whom clin-
ical evaluation is inappropriate or inadequate.
Dialogues Clin Neurosci. 2003;5:89-99.ble sources of diagnostic bias.In addition to these prob-
lems of isolating mild,initial AD from normal aging,the
clinical diagnosis is sometimes ambiguous due to overlap
of symptoms between AD and other dementing illnesses.
To address these issues and improve diagnostic accuracy,
we need to support the clinical diagnosis by laboratory
markers.Many have been sought,
6-8 this article addresses
one of the most promising and best documented,based on
imaging of cerebral structure and function.
Several modalities as well as strategies (eg,quantitative
versus qualitative) have been evaluated for their role in
the imaging diagnosis of AD.Computed tomography (CT)
and magnetic resonance imaging (MRI) have focused pri-
marily on the structural changes observed in specific brain
areas during the course of the disease.Studies evaluating
the diagnosis of AD using these techniques are based on
impressionistic (or interpretive) measures (eg,qualitative
determination of atrophy) or more rigorous quantitative
measures where linear or volumetric parameters are
obtained from the imaging data.The mesial temporal lobe
(MTL),especially the hippocampus,has emerged as the
most sensitive area to examine for AD-related atrophy.
Functional neuroimaging,such as single photon emission
computed tomography (SPECT) or positron emission
tomography (PET),typically measures cerebral perfusion
or metabolism,reflecting alteration in cerebral function.
These studies are also based on either qualitative impres-
sion or objective measured parameters.The area most sen-
sitive to such functional deficits in AD is the inferior pari-
etal cortex.There is a large body of evidence regarding the
validity of both measures (hippocampal atrophy and pari-
etal metabolic deficit) as markers of AD.The relationship
between the two is obscure, and despite their promise,
imaging findings lack compelling evidence for their diag-
nostic value.Recent diagnostic guidelines by the American
Academy of Neurology
9 recommend:
•The National Institutes of Neurological,Communicative
Disorders and Stroke (NINCDS)–Alzheimer’s Disease
and Related Disorders Association (ADRDA) for the
diagnosis of probable AD or Diagnostic and Statistical
Manual of Mental Disorders, Revised Third Edition
(DSM-III-R)
10 criteria for dementia of Alzheimer’s type
(DAT) should be routinely used.
• Structural neuroimaging with either a noncontrast CT
or MRI scan in the routine initial evaluation of
patients with dementia is appropriate.
• Linear or volumetric MRI or CT measurement strate-
gies for the diagnosis of AD are not recommended for
routine use at this time.
• For patients with suspected dementia, SPECT cannot
be recommended for routine use in either initial or dif-
ferential diagnosis,as it has not been demonstrated to
be superior to clinical criteria.
• PET imaging is not recommended for routine use in
the diagnostic evaluation of dementia at this time.
The purpose of this article is to review the neuroimag-
ing literature and suggest avenues of promising research
for AD diagnostics.While we agree with the Academy’s
recommendation against routine neuroimaging in all
cases,we believe that neuroimaging offers unique capa-
bilities for this purpose, which may be extremely useful
in some contexts.As mentioned recently by Hogan and
McKeith,
11 the routine use of structural neuroimaging
may be justifiable merely to detect the 5% of patients
with clinically unsuspected structural lesions.In addition,
we point out here a similarly infrequent,but important,
need for functional imaging. Below we will analyze the
literature with the aim of detecting these specific appli-
cations.
Methods
We performed a computerized search of the indexed med-
ical literature (August 1998–August 2001) through
Medline
® using the following medical subheading (MeSH)
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Selected abbreviations and acronyms
AD Alzheimer’s disease
ADRDA Alzheimer’s Disease and Related Disorders
Association
CAT computed axial tomography
CERAD Consortium to Establish a Registry for
Alzheimer Disease
CT computed tomography
DAT dementia of Alzheimer’s type
DLB dementia with Lewy bodies
MMSE Mini-Mental State Examination
MRI magnetic resonance imaging
MTL mesial temporal lobe
NINCDS National Institutes of Neurological,
Communicative Disorders and Stroke
PET positron emission tomography
PTC parietotemporal cortex
rCBF regional cerebral blood flow
SPECT single photon emission computed tomographyterms: Alzheimer Disease/ AND Diagnostic Imaging/
AND Sensitivity/ AND Specificity/.This search produced
13 citations that directly reported sensitivity and speci-
ficity in diagnosing or distinguishing AD from either
normal or other diseased states (including non-AD
dementia or other mental illness). We additionally
searched the literature for data on the sensitivity and
specificity of clinically based assessments, obtaining 9
studies for comparison.We categorized the results of
each report according to the modality (eg, clinical, CT,
MRI,SPECT,or PET),the strategy (measured or inter-
preted), and comparison group (normal controls or
patients with other dementia types). Studies reporting
sensitivity and specificity data for individual measures
(eg,entorhinal cortex blood flow or sensorimotor cortex
blood flow) were listed as separate entries. We con-
structed a database of these multiple criteria.
Early in the analysis, we encountered a complication in
comparing clinical evaluation against neuroimaging.The
ultimate diagnosis of AD is a neuropathological one.
Clinical diagnosis is usually validated against clinical fol-
low-up, or against postmortem neuropathological diag-
nosis.Neuroimaging studies have usually been validated
against clinical diagnosis.This introduces difficulty into
interpretation of the comparison, since there is a vari-
able error associated with the clinical diagnosis.While it
is not strictly proper to compare the accuracy of imag-
ing diagnosis (against clinical diagnosis) with the accu-
racy of clinical diagnosis (against neuropathological find-
ings),the comparison is heuristically useful.
Results
Clinical diagnosis
To provide a comparison for the accuracy of imaging
data,and evaluate its cost–benefit characteristics,we first
provide information on the accuracy of clinical diagno-
sis against postmortem neuropathology.
Simple screening measures, such as the Mini-Mental
State Examination (MMSE), often provide good diag-
nostic accuracy.For example,Muller et al and Wahlund
et al reported reasonable sensitivity and specificity val-
ues for the MMSE alone and in combination with a ver-
bal recall test.
12,13 More informative results were obtained
with standardized clinical measures when validated
against neuropathological diagnosis. In Jobst et al, 200
affected cases were compared with normal controls by
standardized clinical measures, and then validated with
histopathologic diagnosis.
14 Using NINCDS possible or
probable AD criteria, Jobst et al reported a maximum
sensitivity of 96%,with associated specificity of 61%.In
the same study,the use of DSM-III-R criteria applied to
the same study groups resulted in a sensitivity of 51%,
and specificity of 97%. Other authors, noted in Table I,
obtained similar results.
15-21 Overall, the range of sensi-
tivity of clinical diagnosis was 39% to 98%, and the
range of specificity was 33% to 100%.There was a sig-
nificant negative correlation (r=-0.79, P=0.01) between
sensitivity and specificity,as expected,reflecting the nec-
essary tradeoff.Thus,for instance,to achieve a specificity
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Table I. Sensitivity and specificity of clinical measurements. AD, Alzheimer’s disease; CERAD, CERAD (Consortium to Establish a Registry for Alzheimer
Disease) probable or definite AD (neuropathology); Other, other neuropathological review; DSM-III-R, Diagnostic and Statistical Manual of Mental
Disorders, Revised Third Edition; NINCDS, National Institutes of Neurological, Communicative Disorders and Stroke.
No. AD subjects No. controls Clinical criteria Sensitivity Specificity Neuropathological
criteria
Boller et al,
20 1989 39 15 other NINCDS probable AD 0.95 0.33 Other
Hoffman et al,
15 2000 9 13 other NINCDS probable AD 0.64 0.88 CERAD
Jobst et al,
14 1998 80 38 other NINCDS probable AD 0.49 1.00 CERAD
Jobst et al,
14 1998 80 38 other DSM-III-R 0.51 0.97 CERAD
Kazee et al,
19 1993 94 29 normal NINCDS probable AD 0.98 0.69 Other
Lim et al,
16 1999 84 36 other NINCDS probable AD 0.83 0.55 CERAD
Massoud et al,
17 2000 25 36 other NINCDS probable AD 0.86 0.50 CERAD
Nagy et al,
18 1998 46 27 other NINCDS probable AD 0.41 1.00 CERAD
Nagy et al,
18 1998 46 27 other DSM-III-R 0.39 0.96 CERAD
Tierney et al,
21 1988 22 35 other NINCDS probable AD 0.86 0.89 Othergreater than 80%, four out of five studies had to settle
for sensitivity lower than 70%. This correlation is
depicted in Figure 1.
A number of studies used the criteria “NINCDS possible
or probable AD”or other nonstandard clinical measures
(data not shown).
14-18,20,22-27While clinical diagnosis is often
used to validate imaging findings,and neuro-pathological
diagnosis is the overall “gold standard,”and despite the
existence of modern standardized criteria,the application
of these standards should not be considered free of ambi-
guity.A good example is provided by Hoffman et al.
15The
clinical NINCDS criteria allow the definition of probable
or possible AD,reflecting different degrees of confidence.
The Consortium to Establish a Registry for Alzheimer
Disease (CERAD) pathological criteria allow the finding
of “pure”AD or AD in addition to other pathology.These
authors reported the sensitivity and specificity values for
these four groups of patients (probable/possible clinical
AD validated by pure or nonpure pathological AD diag-
nosis).For these four groups,sensitivity varied from 63%
to 79%,and specificity from 88% to 100%.Discussion of
these issues is outside the scope of this article,but such
distinctions add noise to the data reviewed here and
should be kept in mind when evaluating the material.
When finding such multiple data,we made the choice of
reporting the values for probable AD only, but did not
require “pure”pathological AD.
Computed axial tomography
Two fairly large studies using CT scanning techniques
were available for review.Jobst et al
14 reported diagnos-
tic accuracy based on the measured width of the MTL,
ultimately compared with neuropathology. This tech-
nique resulted in sensitivity of 85% and specificity of
78%. In the same study, they combined this measure-
ment with an impressionistic measure using SPECT to
visualize decreased parietotemporal perfusion.The addi-
tion of the impressionistic measure worsened sensitivity
to 80%, but resulted in improved specificity of 93%.A
second study by Denihan et al
28 compared a series of
patients with AD versus non-AD controls with vascular
dementia, depression, or paraphrenia.This study, also
based on the measured width of the MTL, resulted in
sensitivity of 75% and specificity of 90%.These results
are summarized in Table II.
Magnetic resonance imaging
The application of MRI to the diagnosis of AD is cur-
rently in active research and development, and shows
significant promise.Modern MRI can also provide func-
tional measures, such as cerebral blood volume, blood
flow, and velocity. Some of these measures show great
potential, similar to PET and SPECT (eg, sensitivity of
93% and specificity of 94% for parietotemporal blood
volume relative to cerebellum
29), but this review is only
concerned with structural MRI, as this represents the
most well-studied technique of this imaging modality.
Volumetric analyses of MTL structures show good dis-
crimination from normal aging. However, it is not yet
established which single measure (if any) is best,and the
literature contains references to several measures.In our
search,four studies using MRI reported a total of 22 mea-
surements;the most relevant to the diagnosis of AD are
included in Table III.In comparing subjects with AD ver-
sus normal controls,the best sensitivity/specificity mea-
surements (greater than 80% each) were achieved utiliz-
ing quantitative measurement of hippocampal volume
(95%/92%),
30 entorhinal cortex volume (90%/94%),
31 and
MTL volume (88%/96%).
13 One study
13 reported qualita-
tive impression of MTL volume in combination with the
MMSE,resulting in sensitivity and specificity of 93% and
98%,respectively.This same study also examined the addi-
tion of MRI volumetry to MMSE in distinguishing AD
from other dementia.Sensitivity and specificity in this case
Clinical research
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Figure 1. Sensitivity and specificity of clinical diagnosis against neuro-
pathological diagnosis.
30
50
60
70
80
Specificity (%)
40
90
100
30 40 50 60 70 80 90 100 110
S
e
n
s
i
t
i
v
i
t
y
 
(
%
)was 68% and 53%, respectively. Impression of atrophy
added little to sensitivity and specificity (78% and 64%)
over objective measurement.These data are not included
in the numerical analysis or Figure 2.On observation,how-
ever,these data indicate that the addition of an imaging
measurement adds little to an already relatively high sen-
sitivity for clinical assessment in the case of AD versus nor-
mal controls.
Positron emission tomography
Table IV illustrates the results of PET studies.The most
notable is the report by Silverman et al,
2 which combined
results of 284 PET studies,including 138 with histopatho-
logic diagnoses and the others with 2 years’ clinical fol-
low-up.The scans were interpreted by nuclear medicine
physicians and classified into profiles.AD was identified
(blind to clinical information) with a sensitivity of 94%
and specificity of 73%.Similarly,Hoffman
15 qualitatively
examined parietotemporal (PTC) hypometabolism
achieving sensitivity and specificity of 93% and 63%,
respectively.There were two studies that examined the
distinction of AD from dementia with Lewy bodies
(DLB).
32,33These studies achieved diagnostic sensitivity
of 86% and 92%.The data from these two studies are not
included in the numerical analysis as they represent a
fundamentally different measurement than that used in
the diagnosis of AD and more appropriately represent a
measurement that distinguishes subjects with DLB.
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Table II. Sensitivity and specificity of computed tomography measures. AD, Alzheimer’s disease; CERAD, CERAD (Consortium to Establish a Registry for
Alzheimer Disease) probable or definite AD (neuropathology); NINCDS, NINCDS (National Institutes of Neurological, Communicative Disorders
and Stroke) probable AD (clinical); MTL, mesial temporal lobe; PTC, parietotemporal cortex; rCBF, regional cerebral blood flow; M, measure-
ment; I, impression.
No. AD subjects No. controls Measurement/impression Sensitivity Specificity Diagnostic criteria
Jobst et al,
14 1998 200 119 normal (M) MTL width 0.85 0.78 CERAD
Jobst et al,
14 1998 200 119 normal (M) MTL width 0.80 0.93 CERAD
(I) PTC rCBF
Denihan et al,
28 2000 60 40 other (M) MTL width 0.75 0.90 NINCDS
Table III. Sensitivity and specificity of magnetic resonance imaging measures. AD, Alzheimer’s disease; NINCDS, NINCDS (National Institutes of
Neurological, Communicative Disorders and Stroke) probable AD (clinical); NINCDS possible, NINCDS possible or probable AD (clinical); NINCDS
other, unspecified NINCDS criteria (clinical); rCBV, regional cerebral blood volume; PTC, parietotemporal cortex; MTL, mesial temporal lobe.
No. AD subjects No. controls Measurement Sensitivity Specificity Diagnostic criteria
Harris et al,
29 1998 27 18 normal PTC rCBV  0.93 0.94 NINCDS
Juottonen et al,
31 1999 55 83 other Hippocampal volume 0.90 0.94 NINCDS
Wahlund et al,
13 2000 41 67 normal MTL volume + MMSE 0.88 0.96 NINCDS possible
Golebiowski et al,
30 1999 50 25 normal Hippocampal volume 0.95 0.92 NINCDS other
Figure 2. Summary of sensitivity and specificity of clinical and imaging
modalities. The box plots show the distribution of values in each
category by indicating the 10th, 25th, 50th, 75th, and 90th
percentiles. Values below 10% or above 90% are depicted as
individual points. CT, computed tomography; MRI, magnetic
resonance imaging; PET, positron emission tomography; SPECT,
single photon emission computed tomography.
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The widest variation in diagnostic accuracy overall was
apparent in the studies using SPECT. Seven studies
reported a total of 35 measurements; the most relevant
to the diagnosis of AD are included in Table V.
14,29,34-37The
best sensitivity/specificity in distinguishing subjects with
AD versus normal controls reached 96%/87%, by cal-
culating a discriminant function based on regional cere-
bral blood flow (rCBF) of multiple brain regions.
34
Impressionistic studies of decreased parietotemporal
blood flow achieved a maximal sensitivity/specificity of
89%/80%.
14 One impressionistic study compared sub-
jects with AD with DLB, resulting in sensitivity/speci-
ficity as low as 65%/87%.
35 Sjogren et al
36 examined the
utility of quantitative SPECT in several dementia sub-
types.In each of the reported measurements,specificity
was arbitrarily set at 85%. In subjects with frontotem-
poral dementia,maximal sensitivity/specificity achieved
was 81%/85%, examining the rCBF of the superior
frontal gyrus.In early-stage AD,measurement of rCBF
of the MTL results in sensitivity of 85%.This measure-
ment improved to 96% for subjects with late-stage AD.
Interestingly, measurement of rCBF of the PTC results
in sensitivity of 90% for dementia associated with sub-
cortical white matter disease. Measurements of blood
flow in other brain structures such as white matter,hip-
pocampus, or structures not affected in the particular
dementia under study, resulted in diagnostic sensitivity
often far below 80%,and are not included in this review.
Discussion
Neuroimaging is fairly expensive,complex,and requires
specialized facilities and expertise that may not always be
easily available. Its routine use thus requires rational
examination of cost–benefit considerations.For the pur-
pose of AD diagnosis,the recent Academy of Neurology
report
9 concludes—and this review supports—that clinical
diagnosis can be quite effective.In the most skilled hands
and under favorable conditions, the accuracy of clinical
diagnosis can be very high,as confirmed by histopatho-
logic diagnosis.Sensitivity and specificity data of 85% or
better are commonly reported.Therefore,the routine use
of neuroimaging was not recommended by the recent
Academy report,nor does it appear justified by our data.
While it may be premature to recommend neuroimaging
in all evaluations of dementia,there is a clear role for neu-
roimaging in certain circumstances and, as such, neu-
roimaging may play a role in offering true,objective deter-
minations of the disease state. We agree with the
conclusion that neuroimaging offers,at best,the same level
of diagnostic accuracy as expert clinical assessment.Thus,
from a cost-effectiveness viewpoint, neuroimaging cur-
rently offers no additional benefit over intensive,clinically
based assessments.One must consider,however,that clin-
ical assessment requires a level of expertise,as well as opti-
mal circumstances for test administration that may not
always be possible.Additionally,there are confounding cir-
cumstances compromising the validity and accuracy of
clinical assessment.Three sets of observations suggest that
neuroimaging should be considered,and offers favorable
cost–benefit ratio, in some circumstances.These are: (i)
when clinical expertise is insufficient;(ii) as a complement
to specific likelihood ratios;and (iii) in specific types of
patients.These circumstances are discussed below.
Clinical expertise
An overall summary of this review is provided in Figure
2.Note that all clinical diagnoses were evaluated against
histopathology,whereas some imaging findings were val-
idated by clinical diagnosis. Nevertheless, the data sug-
gest the following observations. First, the specificity of
clinical diagnosis may be better than its sensitivity
(77±26% vs 72±18%, NS in this sample). The mean
specificity of clinical diagnosis compares favorably with
the values offered by neuroimaging, but mean sensitiv-
ity of clinical diagnosis is lower.More striking,however,
are the differences in variance. By any measure of dis-
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Table IV. Sensitivity and specificity of positron emission tomography measures. AD, Alzheimer’s disease; NINCDS, NINCDS (National Institutes of
Neurological, Communicative Disorders and Stroke) probable AD (clinical); CERAD, CERAD (Consortium to Establish a Registry for Alzheimer
Disease) probable or definite AD (neuropathology); Other, other neuropathological criteria; DLB, dementia with Lewy bodies; CMRglu, cere-
bral metabolic rate of glucose; PTC, parietotemporal cortex.
No. AD subjects No. controls Impression Sensitivity Specificity Diagnostic criteria
Hoffman et al,
15 2000 14 8 other PTC hypometabolism 0.93 0.63 CERAD
Silverman et al,
2 2001 97 41 other Cerebral hypometabolism 0.94 0.73 Otherpersion, clinical diagnosis accuracy is far more variable
in this material than the accuracy of any imaging
method.The range of sensitivity of clinical diagnosis is
34% to 95%,and the range of specificity 33% to 100%.
Clearly,these values range from perfect to unacceptable.
This variability of clinical diagnostic accuracy can prob-
ably be attributed to several factors. It includes the rel-
atively large number of studies reviewed,characteristics
of patient and control samples,limited reproducibility of
clinical ratings,and perhaps even different neuropatho-
logical procedures.Another source of variance may be
the result of imperfect clinical criteria. Both NINCDS
and the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV)
38 criteria sets con-
tain features dependent on the skill of the clinician, as
well as features requiring qualitative determination,pos-
sibly rendering the criteria subject to variable interpre-
tation.In the NINCDS criteria,a diagnosis of “probable
AD” requires the establishment of dementia by (i)
MMSE or Blessed Dementia Scale; and (ii) confirma-
tory neuropsychological testing.In addition,there must
be a “progressive worsening of memory and other cog-
nitive functions.”While the former features are for the
most part objective measures, the latter feature is not
specified in detail and might be interpreted in a subjec-
tive manner.The alternative criteria delineated in DSM-
IV do not require objective testing, thus permitting a
diagnosis of AD solely on subjective grounds.Thus, a
clinician employing DSM-IV criteria might diagnose AD
solely from the patient’s history without seeking confir-
matory, objective testing.This approach limits the stan-
dardization of diagnosis and depends heavily on the
diagnostician’s skills.
Indeed, we believe that the main factor responsible for
the variability in clinical diagnosis is the individual skill,
experience,and expertise of the diagnostician.Training,
experience,and insight vary substantially,and probably
affect accuracy. Further, the clinical assessment of AD
occurs primarily in two settings:(i) primary care screen-
ing; and (ii) consultative evaluation of memory or cog-
nitive complaints. Consultative evaluations by memory
specialists are more likely to employ formal testing. In
either setting, the intensity of the evaluation is often
physician-dependent, though clear guidelines exist sug-
gesting appropriate testing and criteria to be used in the
diagnosis.
In contrast,the range of accuracies for imaging findings
is much more limited, typically of the order of 10% to
15%. Imaging procedures are often well standardized,
and commonly performed by technicians as a matter of
fixed routine.While the interpretation of imaging results
is often a matter of skill and expertise,much like clinical
diagnosis,
14AD diagnosis has matured to the extent that
many papers report quantitative, measured results,
rather than an interpretation of patterns.Thus,much of
the variance is removed.
Thus, while the best clinicians under favorable circum-
stances achieve near-perfect diagnostic accuracy (at least
with respect to sensitivity),some clinical evaluations suf-
fer much lower accuracy. Neuroimaging procedures,
especially with measured (rather than interpreted) out-
comes,are much more consistent and much less depen-
dent on individual skills. It appears, thus, that neu-
roimaging procedures can be of significant value in
circumstances where an expert clinician is not readily
available.
Sensitivity and specificity of neuroimaging - Wollman and Prohovnik  Dialogues in Clinical Neuroscience - Vol 5 . No.1 . 2003
95
Table V. Sensitivity and specificity of single photon emission computed tomography measures. AD, Alzheimer’s disease; NINCDS, NINCDS (National
Institutes of Neurological, Communicative Disorders and Stroke) probable AD (clinical); Other, other neuropathological analysis; NINCDS other,
NINCDS unspecified (clinical); NINCDS possible, NINCDS possible AD (clinical); rCBF, regional cerebral blood flow; PTC, parietotemporal cortex;
MTL, mesial temporal lobe; M, measurement; I, impression.
No. AD subjects No. controls Measurement/impression Sensitivity Specificity Diagnostic criteria
Bonte et al,
37 1997 37 16 other (I) rCBF 0.86 0.73 Other
Harris et al,
29 1998 19 18 normal (I) rCBF PTC 0.74 1.00 NINCDS
Jobst et al,
14 1998 80 38 other (I) rCBF PTC 0.89 0.80 NINCDS
Lobotesis et al,
35 2001 50 20 normal (M) rCBF PTC 0.78 0.85 NINCDS other
Sjogren et al,
36 2000 25 (late) 28 normal (M) rCBF MTL 0.96 0.85 NINCDS
Sjogren et al,
36 2000 25 (late) 28 normal (M) rCBF PTC 0.72 0.85 NINCDS
Tsolaki et al,
34 2001 117 41 other (M) rCBF MTL 0.96 0.87 NINCDS possible
Sjogren et al,
36 2000 27 (early) 28 normal (M) rCBF PTC 0.82 0.85 NINCDS
Sjogren et al,
36 2000 27 (early) 28 normal (M) rCBF MTL 0.85 0.85 NINCDSComplementing likelihood ratios
As demonstrated earlier in Figure 1,clinical diagnosis usu-
ally involves a tradeoff between sensitivity and specificity,
even when using standardized clinical scales.Partly as a
function of the scales used,partly depending on explicit or
implicit cutoff selection,and partly due to imperfect relia-
bility,clinical diagnosis commonly offers either good sen-
sitivity or good specificity,but not both.On average,speci-
ficity is better than sensitivity (Figure 2). Further,
circumstances tend to emphasize one or the other. For
example,if treatment is toxic or difficult to institute,speci-
ficity should probably be maximized.On the other hand,
if treatment is benign,but needs to be initiated in the early
stages of the disease,sensitivity is more important.This is
exemplified most clearly by recent suggestions of the rela-
tionship between dementia and statin use
39 or suggestion
of early cholinesterase use in mild cognitive impairment
(MCI).
40 Neuroimaging may help distinguish those indi-
viduals with MCI likely to develop AD.
41
Studies that compared both clinical diagnosis and imaging
findings to eventual neuropathological diagnosis are espe-
cially noteworthy.Hoffman et al,
15 for example,achieved
sensitivity/specificity values of 63%/100% for the clinical
diagnosis of probable AD in a small sample; the corre-
sponding values for the parietotemporal metabolic deficit
were 93%/63%.In this case,therefore,imaging was not
superior overall to clinical examination.However,because
imaging appeared more sensitive and clinical diagnosis,
more specific, overall accuracy could be substantially
improved if the two were combined.Unfortunately,the
sensitivity advantage of imaging is not always reproduced.
Furthermore, while current state of knowledge is not
definitive,there are indications that the various imaging
modalities are not identical with respect to predictive
properties. For example, the current data suggest that
PET offers high sensitivity but lower specificity.It would
therefore be more appropriate in circumstances where
maximal sensitivity is sought.Thus, given more precise
knowledge about the predictive properties of various
clinical and imaging methods, one could complement a
sensitive clinical assessment with a specific imaging pro-
cedure,and vice versa,thus maximizing diagnostic yield.
Patient characteristics
Clinical diagnosis of AD is easier at advanced stages of
the disease; it can be very difficult during the insidious
onset. It is likely that neuroimaging suffers from the
same limitation, although possibly not to the same
extent.
36 Thus, neuroimaging may be especially benefi-
cial in the very early stages.Moreover,once presympto-
matic treatment trials begin,it is likely that neuroimag-
ing may be of unique value in identifying patients likely
to convert to symptomatic status in the future.
In addition to the severity and duration of the disease,
other confounding factors in the clinical diagnosis of AD
include variables such as the patient’s age,level of edu-
cation, and native language. Most patients included in
research protocols are relatively young, whereas most
patients in the population are older.It is not yet known
how clinical diagnostic accuracy varies across the age
span,and in the presence of comorbidities more preva-
lent in the older age range. Education has been shown
to affect the incidence of the disease and/or the likeli-
hood of being diagnosed.
42 Certainly, cognitive perfor-
mance, as measured by screening instruments like the
MMSE, is affected by age as well as education.Those
individuals with advanced education may be character-
ized as normal on initial evaluation, only to be seen in
later courses of the disease when symptoms are more
apparent and the dementia more severe.
43,44We have pre-
viously documented that patients matched for current
clinical dementia severity demonstrate different degrees
of brain damage as measured by imaging procedures.
45
Finally,existing neuropsychological testing in other lan-
guages may not be available (or validated) for
non–native English-speaking subjects.The use of exist-
ing English-based tests in non–native English-speaking
subjects may be inaccurate or insensitive in these cir-
cumstances.
46
Fundamentally, the onset of AD consists of a decline
from premorbid level of functioning. This premorbid
level, the “normal” level, is extremely variable in the
normal population across age, language skills, educa-
tional and occupational background,etc.For this reason,
it is difficult to clinically assess decline in the absence of
strong documentation of premorbid functioning.
Neuroimaging may offer this capability.We have previ-
ously shown that the parietotemporal perfusion deficit
is strongly related to this decline, even more strongly
than to current dementia severity.
45 Thus, the funda-
mental measurement of decline from premorbid levels
may be possible with functional neuroimaging. If con-
firmed in future studies,this capability may overcome all
factors currently confounding clinical diagnosis:regard-
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ground,or age,we may be able to define how much their
brain function has declined from what was,for each indi-
vidual patient,normal levels.This decline may well be a
better predictor of progression or medication response
than current clinical symptomatology.
Conclusion
We have reviewed the recent literature on neuroimag-
ing diagnosis of AD.As in any conclusions based on a lit-
erature review or meta-analysis,the possibility of a pub-
lication bias must be considered. It is possible that
unsuccessful imaging studies (ie, those reporting low
diagnostic accuracy) are not published, due to reserva-
tions by authors or editors.It is also possible that imag-
ing papers tend to be submitted to specific journals,with
publication policies different from those of other,more
purely clinical, journals. Finally, some papers may have
been published in journals not indexed by Medline.
Thus, further consideration of our conclusions must be
bound by the nature of the material and its limitations.
Our interpretation of this literature offers two main con-
clusions.First,that the variability of diagnostic accuracy
is considerably lower than that of clinical diagnosis.In
particular,while neuroimaging cannot improve the best
clinical diagnosis findings (which are close to 100%),the
lowest accuracies reported for imaging are considerably
higher than the lowest accuracies reported for clinical
diagnosis (Figure 2).Thus,imaging can serve to signifi-
cantly improve the lower bounds of diagnostic accuracy.
Second,we propose that imaging adds unique informa-
tion to the diagnostic process that may not be available
by any other methods.This information may be especially
pertinent in certain clinical situations,discussed above.
Both clinical criteria and imaging procedures are con-
tinuously evolving,and they need to continue to be used
together for further evaluation.While MRI appears to
be superior overall in this material (Figure 2), the cur-
rent work was not designed to compare the relative mer-
its of various imaging modalities. Studies that employ
more than one imaging modality are rare but useful,and
more need to be conducted.For example,De Santi et al
41
compared PET-derived glucose metabolism and MRI-
derived volumetric measures in temporal lobe struc-
tures.They concluded, overall, that neocortical (middle
and superior temporal gyrus) measures were more accu-
rate than hippocampal structures, and that functional
PET measures were superior to MRI findings in dis-
criminating AD from normal controls.Like others,these
authors showed that the relative classification merit of
various structures in and around the hippocampal for-
mation is variable,and there is still no agreement on the
most informative structures. Because sensitivity/speci-
ficity values were not rigorously reported, we did not
include this study in our tables and figures, but clearly
more studies of this type are necessary. ❏
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Sensibilidad y especificidad de las 
neuroimágenes en el diagnóstico de la
Enfermedad de Alzheimer
La Enfermedad de Alzheimer (EA) es uno de los tras-
tornos más devastadores y de alto costo que afecta a
la población senescente. Por su papel en el diagnós-
tico imagenológico de la EA se ha evaluado la ima-
genología estructural (tomografía computada [TC] y
resonancia nuclear magnética [RNM]) y la imageno-
logía funcional (tomografía computada por emisión
de fotón único [SPECT] y tomografía por emisión de
positrones [PET]). Se ha revisado la literatura reciente
para determinar las capacidades de estas técnicas de
neuroimágenes en comparación con los estándares
actuales del diagnóstico clínico. Nuestros resultados
señalan que existe una amplia variabilidad en la
exactitud de las evaluaciones clínicas en contraste con
un rango más limitado de variabilidad de la exacti-
tud de las mediciones de las neuroimágenes. Estos
resultados sugieren que la neuroimagenología puede
servir como método complementario para elevar este
menor límite de la exactitud diagnóstica. Por último,
se sugiere que las neuroimágenes se deben tener en
consideración (i) cuando la experiencia clínica es insu-
ficiente, (ii) como complemento para frecuencias
específicas de probabilidad y (iii) en algunos pacien-
tes especiales, para quienes la evaluación clínica es
inapropiada o no es suficiente.
Sensibilité et spécificité de la neuro-
imagerie pour le diagnostic de la maladie
d’Alzheimer
La maladie d’Alzheimer (MA) est l’un des troubles
les plus dévastateurs et coûteux touchant la popu-
lation âgée. L’imagerie structurale (tomodensito-
métrie et IRM) et l’imagerie fonctionnelle (SPECT et
PET) ont été évaluées pour leur rôle dans le dia-
gnostic de la MA. Nous avons passé en revue la lit-
térature récente pour déterminer les capacités de
ces techniques de neuro-imagerie comparées aux
méthodes de référence actuelles de diagnostic cli-
nique. Nos résultats montrent qu’il y a une grande
variabilité dans la fidélité des évaluations cliniques
par opposition à une moins grande variabilité de
l’exactitude des mesures réalisées grâce à la neuro-
imagerie. Ces résultats suggèrent que la neuro-ima-
gerie peut jouer un rôle d’appoint pour améliorer
la limite inférieure de l’exactitude du diagnostic. De
plus, nous suggérons que la neuro-imagerie devrait
être envisagée : (i) lorsque l’expertise clinique est
insuffisante ; (ii) comme complément aux rapports
de probabilité spécifiques ; et (iii) pour des types
particuliers de patients pour lesquels une évalua-
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